Home › Compare › KGAUF vs ABBV
KGAUF yields 1000.00% · ABBV yields 3.06%● Live data
📍 KGAUF pulled ahead of the other in Year 1
Combined, KGAUF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KGAUF + ABBV for your $10,000?
Kongsberg Automotive ASA develops, manufactures, and sells products to the automotive industry worldwide. The company operates through Powertrain & Chassis and Specialty Products segments. The Powertrain & Chassis segment designs, manufactures, and tests custom powertrain and chassis solutions, including gear shifters for automatic and manual transmissions, shift cables and towers, and vehicle dynamics products for cabins and axles, as well as gear and clutch control systems comprise of actuators. The Specialty Products segment offers fluid handling systems; couplings systems for compressed-air circuits in heavy-duty vehicles; and operator control systems for power sports construction, agriculture, outdoor power equipment, and power electronics products. It serves OEMs and Tier 1 suppliers in the automotive, commercial vehicle, and off-highway markets. The company was formerly known as Kongsberg Automotive Holding ASA and changed its name to Kongsberg Automotive ASA in August 2014. Kongsberg Automotive ASA was founded in 1957 and is based in Kongsberg, Norway.
Full KGAUF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.